Hormonal Modulation of HER-2/neu Protooncogene Messenger Ribonucleic Acid and pl85 Protein Expression in Human Breast Cancer Cell Lines

Cancer Research

Volumn 50, Issue 13, 1990, Pages 3947-3951

  Read, Linnea D ^a   Keith, Duane ^b   Slamon, Dennis J ^b   Katzenellenbogen, Benita S ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; ESTRADIOL; ESTROGEN RECEPTOR; MESSENGER RNA; MIFEPRISTONE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; PROGESTERONE RECEPTOR; PROMEGESTONE; RADIOISOTOPE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CELL CULTURE; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL; TUMOR CELL LINE;

BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; ESTROGENS; HUMAN; MIFEPRISTONE; NEOPLASMS, HORMONE-DEPENDENT; PROGESTATIONAL HORMONES; PROGNOSIS; PROMEGESTONE; PROTO-ONCOGENE PROTEINS; PYRROLIDINES; RECEPTOR, ERBB-2; RNA, MESSENGER; RNA, NEOPLASM; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; THIOPHENES; TUMOR CELLS, CULTURED;

EID: 0025374582     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Slarnon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Wash. DC), 244: 707–712, 1989.
2. Schechter, A. L., Stern, D. F., Vaidyanathan, L., Decker, S. J., Drebin, J. A., and Greene, M. I., and Weinberg, R. A. The neu oncogene: an erb-B-related gene encoding a 185, 000-Mr tumour antigen. Nature (Lond.), 312: 513–516, 1984.
3. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Wash. DC), 235: 177–182, 1987.
4. Masuda, H., Battifora, H., Yokota, J., Meltzer, S., and Cline, M. J. Specificity of proto-oncogene amplification in human malignant diseases. Mol. Biol. Med., 4: 213–227, 1987.
5. Mattson, W. Current status of high dose progestin treatment in advanced breast cancer. Breast Cancer Res. Treat., 3: 231–235, 1983.
6. Horwitz, K. B., and Freidenberg, G. R. Progestins inhibit growth and increase insulin receptors in antiestrogen resistant T47Dco cells: implications for endocrine therapies. Cancer Res., 45: 167–173, 1985.
7. Chalbos, D., and Rochefort, H. Dual effects of the progestin R5020 on proteins released by the T47D human breast cancer cells. J. Biol. Chem., 259: 1231–1238, 1984.
8. Osborne, C. K., Yochmowitz, M. G., Knight, W. A., and McGuire, W. L. The value of estrogens and progestins in the treatment of breast cancer. Cancer (Phila.), 46: 2884–2888, 1980.
9. Lippman, M. E. Endocrine responsive cancers in man. In: Williams, R. H. (ed), Textbook of Endocrinology, pp, 1309–1326. Philadelphia: W. B. Saunders Co., 1985.
10. Miller, M. A., and Katzenellenbogen, B. S. Characterization and quantitation of antiestrogen binding sites in estrogen receptor-positive and -negative human breast cancer cell lines. Cancer Res., 43: 3094–3100, 1983.
11. Katzenellenbogen, B. S., Kendra, K. L., Norman, M. J., and Berthois, Y. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res., 47: 4355–4360, 1987.
12. Dickson, R. B., Huff, K. K., Spencer, E. M., and Lippman, M. E. Induction of EGF-related polypeptides by 170-estradiol in MCF-7 human breast cancer cells. Endocrinology, 118: 138–142, 1986.
13. Wilding, G., Lippman, M. E., and Gelmann, E. P. Effects of steroid hormones and peptide growth factors on protooncogene c-fos expression in human breast cancer cells. Cancer Res., 48: 802–805, 1988.
14. Dickson, R. B., McManaway, M. E., and Lippman, M. E. Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. Science (Wash. DC), 232: 1540–1543, 1986.
15. Dubik, D., Dembinski, T. C., and Shiu, R. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res., 47: 6517–6521, 1987.
16. Sapino, A., Pietribiasi, F., Bussolati, G., and Marchisio, P. C. Estrogen- and tamoxifen-induced rearrangement of cytoskeletal and adhesion structures in breast cancer MCF-7 cells. Cancer Res., 46: 2526–2531, 1986.
17. Huff, K. K., and Lippman, M. E. Hormonal control of plasminogen activator secretion in ZR-75–1 human breast cancer cells in culture. Endocrinology, 114: 1702–1710, 1984.
18. Albini, A, Graf, J. G., Kitten, G. T., Kleinman, H. K., Martin, G. R., Veillette, A., and Lippman, M. E., 170-Estradiol regulates and v-Ha-ras transfection constitutively enhances MCF-7 breast cancer cell interactions with basement membrane. Proc. Natl. Acad. Sci. USA, 83: 8182–8186, 1986.
19. Capony, F., Morrisset, M., Barrett, A. J., Capony, J. P., Broguet, P. B., Vignon, F., Chambon, M., Louisot, P., and Rochefort, H. Phosphorylation, glycosylation and proteolytic activity of the 52-kD estrogen induced protein secreted by MCF-7 cells. J. Cell. Biol., 104: 253–262, 1987.
20. Coezy, E., Borgna, J-L, and Rochefort, H. Tamoxifen and metabolites in MCF-7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res., 42: 317–323, 1982.
21. Katzenellenbogen, B. S., Miller, M. A., Mullick, A., and Sheen, Y. Y. Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites. Breast Cancer Res. Treat., 5: 231–243, 1985.
22. Thompson, E. W., Katz, D., Shima, T. B., Wakeling, A. E., Lippman, M. E., and Dickson, R. B. ICI 164, 384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness. Cancer Res., 49: 6929–6934, 1989.
23. Clarke, R., Brunner, N., Katzenellenbogen, B. S., Thompson, E. W., Norman, M. J., Koppi, C., Paik, S., Lippman, M. E., and Dickson, R. B. Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. Proc. Natl. Acad. Sci. USA, 86: 3649–3653, 1989.
24. Berthois, Y., Katzenellenbogen, J. A., and Katzenellenbogen, B. S. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc. Natl Acad. Sci., USA, 83: 2496–2500, 1986.
25. Eckert, R. L., and Katzenellenbogen, B. S. Effects of estrogens and antiestrogens on estrogen receptor dynamics and the induction of progesterone receptor in MCF-7 human breast cancer cells. Cancer Res., 42: 633–642, 1982.
26. Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., and Rutter, W. J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry, 18: 5294–5299, 1979.
27. Read, L. D., Snider, C. E., Miller, J. S., Greene, G. L., and Katzenellenbogen, B. S. Ligand-modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines. Mol. Endocrinol., 2: 263–271, 1988.
28. McKearin, D. M., Barton, M. C., Keller, M. J., and Shapiro, D. J. Estrogen induces transcription of the Xenopus laevis serum retinol binding protein gene. J. Biol. Chem., 262: 4939–4942, 1987.
29. Maniatis, T. M., Fritsch, E. F., and Sambrook, J. Molecular Cloning: A Laboratory Manual, pp. 202–203. Cold Spring Harbor, NY: Cold Spring Harbor Laboratories, 1982.
30. Hanukoglu, I., Tanese, N., and Fuchs, E. Complementary DNA sequence of a human cytoplasmic actin: interspecies divergence of 3′ non-coding regions. J. Mol. Biol., 163: 673–678, 1983.
31. Feinberg, A. P., and Vogelstein, B. A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem., 757: 266–267, 1984.
32. Church, G. M., and Gilbert, W. Genomic sequencing. Proc. Natl. Acad. Sci. USA, 81: 1991–1995, 1984.
33. Slamon, D. J., Press, M. F., Godolphin, W., Ramos, L., Haran, P., Shek, A., Stuart, S. G., and Ullrich, A. Studies of the HER-2/neu oncogene in human breast cancer. Cancer Cells, 7: 371–384, 1989.
34. Mangel, W. F., Toledo, D. L., Nardulli, A. M., Reiner, G. A., Norman, M. J., and Katzenellenbogen, B. S. Plasminogen activators in human breast cancer cell lines: hormonal regulation and properties. J. Steroid Biochem., 50: 79–88, 1988.
35. Read, L. D., Greene, G. L., and Katzenellenbogen, B. S. Regulation of estrogen receptor messenger ribonucleic acid and protein levels in human breast cancer cell lines by sex steroid hormones, their antagonists, and growth factors. Mol. Endocrinol., 5: 295–304, 1989.
36. Wakeling, A. E., and Bowler, J. Steroidal pure antiestrogens. J. Endocrinol., 112: R7-R10, 1987.
37. Yamamoto, T., Ikawa, S., Akiyama, T., Semba, K., Nomura, N., Miyajima, N., Saito, T., and Toyoshima, K. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature (Lond.), 319: 230–234, 1986.
38. King, C. R., DiFiore, P. P., Pierce, J. H., Segatto, O., Kraus, M. H., and Aaronson, S. A. Oncogenic potential of the erbB-2 gene: frequent overexpression in human mammary adenocarcinomas and induction of transformation in vitro. In: Growth Regulation of Cancer, pp, 189–199, New York: Plenum Press, 1988.
39. Bargmann, C. I., Hung, M-C. and Weinberg, R. A. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of pl85. Cell, 45: 649–649, 1986.
40. Fontaine, J., Tesseraux, M., Klein, V., Bastert, G., and Blin, N. Gene amplification and expression of the (c-erbB-2) sequence in human mammary carcinoma. Oncology, 45: 360–366, 1988.
41. Hudziak, R. M., Lewis, G. D., Shalaby, M. R., Eessalu, T. E., Aggarwal, B. B., Ullrich, A., and Shepard, H. M. Amplified expression of the HER/ERBB2 oncogene induces resistance to tumor necrosis factor a in NIH 3T3 cells. Proc. Natl. Acad. Sci. USA, 85: 5102–5106, 1988.
42. Rio, M. C., Bellocq, J. P., Gairard, B., Rasmussen, U. B., Krust, A., Koehl, C., Calderoli, H., Schiff, V., Renaud, R., and Chambon, P. Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. Proc. Natl. Acad. Sci. USA, 84: 9243–9247, 1987.
43. Wright, C., Angus, B., Nicholson, S., Sainsbury, J. R. C., Cairns, J., Gullick, W. J., Kelly, P., Harris, A. L., and Wilson Home, C. H. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res., 49: 2087–2090, 1989.
44. Horwitz, K. B., Zava, D. T., Thilagar, A. K., Jensen, E. M., and McGuire, W. L. Steroid receptor analysis of nine human breast cancer cell lines. Cancer Res., 38: 2434–2437, 1978.
45. Vuorio, T., Warri, A., Sandberg, M., Alitalo, K., and Vuorio, E. Expression of the c-Ha-ros and neu oncogenes in DMBA-induced, anti-estrogen-treated rat mammary tumors. Int. J. Cancer, 42: 774–779, 1988.
46. Cohrs, R. J., Goswami, B. B., and Sharma, O. K. Down-regulation of c-myc, c-fos, and erb-b during estrogen induced proliferation of the chick oviduct. Biochem. Biophys. Res. Commun., 150: 82–88, 1988.
47. Yarden, Y., and Weinberg, R. A. Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene. Proc. Natl. Acad. Sci. USA, 86: 3179–3183, 1989.
48. Bargmann, C. I., and Weinberg, R. A. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. Proc. Natl. Acad. Sci. USA, 85: 5394–5398, 1988.
49. Bates, S. E., Davidson, N. E., Valverius, E. M., Freter, C. E., Dickson, R. B., Tarn, J. P., Lippman, M. E., and Salomon, D. S. Expression of transforming growth factor a and its messenger ribonucleic acid in human brest cancer: its regulation by estrogen and its possible functional significance. Mol. Endocrinol., 2: 543–555, 1988.
50. Dickson, R. B., Bates, S. F., McManaway, M. E., and Lippman, M. E. Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Cancer Res., 46: 1707–1713, 1986.
51. Kokai, Y., Dobashi, K., Weiner, D. B., Myers, J. N., Nowell, P. C., and Greene, M. I. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products. Proc. Natl. Acad. Sci. USA, 85: 5389–5393, 1988.
52. Akiyama, T., Saito, T., Ogawara, H., Toyoshima, K., and Yamamoto, T. Tumor promoter and epidermal growth factor stimulate phosphorylation of the c-erb N-2 gene product in MKN-7 human adenocarcinoma cells. Mol. Cell. Biol., 8: 1019–1026, 1988.
53. Meyer, J. S., McDivitt, R. W., Stone, K. R., Prey, M. U., and Bauer, W. C. Practical breast carcinoma cell kinetics: review and update. Breast Cancer Res. Treat., 4: 79–88, 1984.
54. Read, L. D., Keith, D., Slamon, D. J., and Katzenellenbogen, B. S. Hormonal modulation of HER-2/neu oncogene expression in human breast cancer cell lines. Proc. Am. Assoc. Cancer Res., 30: 456, 1989.